source
- Shionogi receives FDA nod for first oral COVID-19 post-exposure prevention pillShionogi announced that the U.S. Food and Drug Administration has granted approval for its oral antiviral designed to prevent COVID-19 after exposure. The product is indicated for adults and child…
- Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenibAgios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib. Under the agreement, Agios will pay $25 million up front to Oscot…